Merck
Q2 2023 Earnings

August 1, 2023
Agenda

Strategy and Business Update

Rob Davis
Chairman and Chief Executive Officer

Business/Financial Results and Outlook

Caroline Litchfield
Chief Financial Officer

Research Update

Dr. Dean Li
President, Merck Research Laboratories

Question & Answer Session
Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA

This presentation of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2022 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
Strategy & Business Update

Rob Davis
Chairman and Chief Executive Officer
Delivered on our key strategic priorities in Q2 2023

- Advanced the pipeline to meet patient unmet need
- Executed on strategic business development to enhance pipeline
- Achieved strong commercial and financial performance
- Created long-term value for patients and shareholders
Strong underlying Q2 performance

**Q2 Worldwide Sales**

$15.0B

+3%

+14% ex-Exchange, ex-LAGEVRIO

**Q2 Non-GAAP LPS**

($2.06)

N/M

Includes one-time charge of $4.02 from Prometheus acquisition

---

**Full Year Sales**

- **2021**: $48.7B (+17%)
- **2022**: $59.3B (+22%)
- **2023**: Guidance range $58.6B - $59.6B

**Full Year Non-GAAP EPS**

- **2021**: $5.37
- **2022**: $7.48
- **2023**: Guidance range $2.95 - $3.05

---

1. Results from continuing operations attributable to Merck & Co., Inc. 2. Excludes Lagevrio sales of $203 million in 2Q23 and $1.2 billion in 2Q22. 3. GAAP EPS (Loss Per Share) of ($2.35). Both 2Q23 GAAP and non-GAAP LPS reflect a charge of $10.2 billion or $4.02 per share for the acquisition of Prometheus Biosciences, Inc. 4. Not meaningful 5. Merck does not exclude expenses for upfront and milestone payments related to collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. YTD 2023 non-GAAP results include an aggregate $11.6 billion or $4.53 per share of R&D expenses related to the Prometheus and Imago acquisitions and upfront payment for the license and collaboration agreement with Kelun. Full year 2022 non-GAAP results include $690 million or $0.22 of such charges. For 2023, outlook does not assume any additional significant potential business development transactions.
Advancing and augmenting our deep pipeline

**Oncology**

- Highlighted important data at ASCO:
  - **KEYNOTE-671** for neoadjuvant and adjuvant for the treatment of non-small cell lung cancer
  - **KEYTRUDA** in combination with **V940**, our Individualized Neoantigen Therapy (INT) for the treatment of adjuvant melanoma
  - **MK-2870**, our TROP-2 ADC, for the treatment of non-small cell lung cancer

**Vaccines and Infectious Disease**

- Announced **positive topline results for V116**, our pneumococcal conjugate vaccine candidate specifically designed for adults

**General Medicine**

**Cardiometabolic**

- Completed FDA submission of **sotatercept** in PAH based on the Phase 3 STELLAR trial
- Presented **Phase 2a data** at EASL for efinopegduvide, our **GLP-1/glucagon receptor co-agonist**, in **NAFLD**

**Immunology**

- Completed acquisition of **Prometheus Biosciences**
Putting the patient at the center of everything we do

Guided by our purpose to continue advancing innovative science and broadening access to patients around the world

2022/2023 Impact Report¹ forthcoming

1. Formerly called the ESG report
Business/Financial Results and Outlook

Caroline Litchfield
Chief Financial Officer
Merck

WORLDWIDE SALES\(^1,2\)

\$15.0B

+3% growth
+11% ex-LAGEVRIO\(^3\)
+14% ex-exchange, ex-LAGEVRIO\(^3\)

Human Health

\$13.5B

+6% growth
+14% ex-LAGEVRIO\(^3\)
+17% ex-exchange, ex-LAGEVRIO\(^3\)

Animal Health

\$1.5B

-1% growth
+2% ex-exchange

---

1. Results attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue. 3. Excludes Lagevrio sales of $203 million in 2Q23 and $1.2 billion in 2Q22.
Oncology: KEYTRUDA continues to drive strong growth

- KEYTRUDA sales of $6.3B increased 21% year-over-year, driven by uptake in earlier stage cancers and continued strong global demand from metastatic indications
  - In the U.S., growth of 21% reflects strong utilization across earlier stage cancers such as TNBC, as well as certain types of RCC and melanoma
  - Ex-U.S., 22% increase driven by demand in metastatic RCC and certain types of H&N cancer, as well as earlier stage cancers, including high-risk early stage TNBC and RCC

Growth rates exclude the impact of foreign exchange.
Oncology: Solid performance across broad portfolio

• Lynparza\(^1\) sales grew 15% driven primarily by increased demand in certain international markets

• Lenvima\(^2\) sales grew 6% due to demand in advanced RCC and endometrial cancer in the U.S., partially offset by lower sales in China

\(^1\) In collaboration with AstraZeneca  \(^2\) In collaboration with Eisai
Vaccines: Exceptional growth driven by GARDASIL

• GARDASIL sales of $2.5B increased 53% year-over-year primarily driven by strong global demand, particularly in China
  – China growth is benefitting from the expanded indication of GARDASIL 9 to females ages 9 to 45
• Strong ongoing pediatric launch of VAXNEUVANCE

Growth rates exclude the impact of foreign exchange.
Hospital: Strong demand across key products

- BRIDION sales of $502M increased 19% primarily due to greater share among neuromuscular blockade reversal agents in the U.S.

- PREVYMIS sales grew 42% driven by continued strong global demand

Growth rates exclude the impact of foreign exchange.
Animal Health: Growth driven by livestock and companion animal

• Animal Health sales increased 2% to $1.5B
  – Livestock growth of 2% reflects price actions and increased demand for swine and poultry products, partially offset by lower demand for ruminant products due in part to reduced herd sizes
  – Companion Animal growth of 2% reflects price actions including for BRAVECTO, partially offset by supply challenges for certain vaccines

Growth rates exclude the impact of foreign exchange.
# Q2 2023 non-GAAP financial results summary

<table>
<thead>
<tr>
<th></th>
<th>Q2 2023</th>
<th>Q2 2022</th>
<th>Change</th>
<th>Change Ex-FX</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sales</strong></td>
<td>$15.0</td>
<td>$14.6</td>
<td>+3%</td>
<td>+7%</td>
</tr>
<tr>
<td><strong>Non-GAAP Gross Margin</strong></td>
<td>76.6%</td>
<td>74.7%</td>
<td>+1.9pts</td>
<td>+2.7pts</td>
</tr>
<tr>
<td><strong>Non-GAAP Operating Expenses</strong></td>
<td>$15.9</td>
<td>$5.2</td>
<td>N/M</td>
<td>N/M</td>
</tr>
<tr>
<td><strong>Non-GAAP Tax Rate</strong></td>
<td>-18.4%</td>
<td>13.8%</td>
<td>-32.2pts</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Non-GAAP Earnings / (Loss) Per Share</strong></td>
<td>($2.06)</td>
<td>$1.87</td>
<td>N/M</td>
<td>N/M</td>
</tr>
</tbody>
</table>

1. Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q2 2023 non-GAAP results include $10.2 billion of R&D expense or $4.02 of negative impact to EPS, related to the acquisition of Prometheus Biosciences. 3. Q2 2023 provision for Taxes on Income was $810 million. A pre-tax loss was recorded this quarter due to the Prometheus one-time charge, which was not tax deductible. As a result, the tax rate was negative in the quarter. 4. Q2 2023 GAAP LPS of ($2.35).
Merck updated full-year 2023 guidance

<table>
<thead>
<tr>
<th>Prior Guidance</th>
<th>Updated Guidance</th>
<th>Key Assumptions</th>
</tr>
</thead>
</table>
| **Revenue**    | $57.7B to $58.9B | $58.6B to $59.6B| • Includes approximately $1B of LAGEVRIO revenue  
                | -3% to -1% (-1% to +1% ex-FX) | -1% to +1% (+1% to +3% ex-FX)  
                |                               | • Ex-LAGEVRIO, growth of 8% to 9% (10 to 11% ex-FX)  
                |                               | • Assumes 2 ppt FX headwind  |
| **Non-GAAP Gross Margin Rate** | ~77.0% | ~77.0% | |
| **Non-GAAP Operating Expenses** | $23.3B to $24.1B | $34.0B to $34.6B | • Includes additional $10.2B related to upfront charge for the acquisition of Prometheus and investment to advance the acquired assets  
| **Other (Income) / Expense** | ~$250M of income | ~$100M of expense | • Includes financing costs related to the acquisition of Prometheus  
| **Tax Rate** | ~17.0% to 18.0% | ~30.5% to 31.5% | • Includes ~15 ppt negative impact from the acquisition of Prometheus  
| **Shares Outstanding** | ~2.55B | ~2.55B | • Assumes modest share repurchase  
| **Non-GAAP EPS** | $6.88 to $7.00 | $2.95 to $3.05 | • Includes $4.02 one-time charge for the Prometheus acquisition and an additional $0.14 to advance the assets and finance the transaction  
  |                               |                               | • Assumes 5 ppt FX headwind (additional $0.02 headwind)  

1. Includes an aggregate $11.6 billion of R&D expenses related to the Prometheus and Imago acquisitions and upfront payment for the license and collaboration agreement with Kelun. Outlook does not assume any additional significant potential business development transactions. 2. Includes $4.53 of one-time charges related to the Prometheus and Imago acquisitions and upfront payment to Kelun.
Key modeling considerations

**KEYTRUDA**

- Anticipate strong year-over-year growth, but not quite at the levels experienced in recent quarters
- Continue to expect strong volume growth to be partially offset by pricing headwinds, particularly in key European markets
- In the second quarter, there was a small benefit from wholesaler purchase timing in the U.S. which is expected to reverse in the third quarter

**GARDASIL**

- Expect the pace of full year growth to be higher in 2023 relative to 2022, with first half growth above that of the second half due in part to the timing of shipments in China
Remain committed to balanced capital allocation strategy

$ Billions

Capital allocation order of priority

Continue to invest in our pipeline and business while augmenting our pipeline with value enhancing business development.

1. Reflects Q2 spend.  2. Includes payment for the Prometheus acquisition.

After-Tax R&D: $2.6
CapEx: $1.0
Dividends Paid: $1.9
Business Development (ex-divestitures): $10.9
Share Repurchase: $0.3
Research Update

Dr. Dean Li
President, Merck Research Laboratories
Driving value for patients and shareholders by progressing our pipeline

Key regulatory milestones since the last earnings call:

- **In the U.S., the FDA:**
  - Granted approval of Lynparza\(^1\) in combination with abiraterone and prednisone in patients with deleterious or suspected deleterious BRCAm metastatic castration-resistant prostate cancer
  - Accepted sBLA for KEYTRUDA in combination with chemotherapy in patients with locally advanced unresectable or metastatic biliary tract cancer
  - Approved a new indication for PREVYMIS for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk
  - Accepted the re-submission of NDA for gefapixant in patients with refractory or unexplained chronic cough
- **In the EU, the EMA:**
  - Accepted sMAA for KEYTRUDA in combination with trastuzumab and chemotherapy in patients with locally advanced unresectable or metastatic HER2- positive gastric or gastroesophageal junction adenocarcinoma
  - Received positive CHMP opinion for gefapixant in patients with refractory or unexplained chronic cough
- **In Japan, the PMDA:**
  - Granted approval of KEYTRUDA in patients with relapsed or refractory primary mediastinal B-cell lymphoma
  - Accepted sJNDA for KEYTRUDA in combination with chemotherapy in 1L treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, as well as in patients with locally advanced unresectable or metastatic biliary tract cancer
  - Granted approval of VAXNEUVANCE in pediatrics
- **In China, the CDE:**
  - Granted approval of Koselugo\(^1\) for the treatment of symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type I ages 3 years and older

Key data & clinical advancements since the last earnings call:

- Presented data across broad oncology portfolio at ASCO, including for KEYTRUDA (KN-671, KN-483, KN-581, KN-716, KN-826), Lenvima\(^2\), Lynparza\(^1\), WELIREG, mRNA-4157/V940\(^3\) (INT) and MK-2870/SKB264\(^4\) (TROP2 ADC)
- Announced positive topline results for KN-811 evaluating KEYTRUDA in combination with trastuzumab as 1L treatment in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma in PD-L1 positive patients
- Announced Phase 3 KN-A18 trial met primary endpoint of progression-free survival in patients with newly diagnosed high-risk locally advanced cervical cancer
- Announced Phase 3 KN-756 trial met one of its dual primary endpoints of pathological complete response rate in patients with high-risk, early-stage ER+/HER2- breast cancer
- Presented Phase 2a data at EASL for efinopegdu tide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, in patients with nonalcoholic fatty liver disease (NAFLD), which has advanced to Phase 2b in nonalcoholic steatohepatitis (NASH)
- Completed BLA submission of sotatercept for pulmonary arterial hypertension (PAH) to the FDA
- Announced positive topline results from two Phase 3 trials evaluating V116 in vaccine-naïve and previously vaccinated individuals

---

1. In collaboration with AstraZeneca  
2. In collaboration with Eisai  
3. In collaboration with Moderna  
4. In collaboration with Kelun
Continuing to advance our broader oncology program

Clinical progress

- **KEYNOTE-756**: Phase 3 trial met one of its dual primary endpoints of pCR for treatment of patients with high-risk early-stage ER+/HER2- breast cancer

- **KEYNOTE-A18**: Phase 3 trial met one of its primary endpoints of PFS for treatment of patients with high-risk locally advanced cervical cancer

- Promising data presented at ASCO:
  - **KEYNOTE-671**: KEYTRUDA perioperative regimen reduced risk of disease recurrence, progression, or death by 42% in patients with resectable stage II, IIIA or IIIB NSCLC
  - **KEYNOTE-942**: V9401 (INT) and KEYTRUDA reduced risk of distant metastasis or death by 65% in patients with stage III/IV melanoma following complete resection
    - Initiated Phase 3 trial for adjuvant treatment of high risk, stage II to IV melanoma
  - **MK-2870**: Showed encouraging anti-tumor activity in patients with locally advanced or metastatic NSCLC

Regulatory updates

- **PROpel**: received FDA approval for Lynparza³ in combination with abiraterone and prednisone in patients with deleterious or suspected deleterious BRCA-mutated mCRPC

- **KEYNOTE-966**: sBLA for KEYTRUDA in combination with chemotherapy in patients with locally advanced unresectable or metastatic biliary tract cancer accepted for FDA review

- **KEYNOTE-811**:
  - KEYTRUDA in combination with trastuzumab and chemotherapy showed significant improvement in PFS in 1L treatment of HER2-positive advanced gastric or GEJ adenocarcinoma in patients whose tumors were PD-L1 positive
  - Received positive EMA opinion

---

1. In collaboration with Moderna  
2. In collaboration with Kelun  
3. In collaboration with AstraZeneca
Progressing our broader pipeline

### Vaccines and Infectious Disease

- **V116**, our investigational pneumococcal conjugate vaccine specifically designed for adults:
  - protects against serotypes that are responsible for ~85% of invasive pneumococcal disease in adults ages ≥65¹
  - includes 8 serotypes that are currently not covered by approved vaccines, and are responsible for ~30% of invasive pneumococcal disease in adults ages ≥65¹
- Announced positive topline data for V116 for two Phase 3 trials (STRIDE-3 and STRIDE-6)
- Received FDA approval for PREVYMIS for prophylaxis of CMV disease for adult recipients of kidney transplant who are at high-risk of infection

### General Medicine

- Completed FDA submission of sotatercept for the treatment of adults with PAH based on the Phase 3 STELLAR trial
- Presented positive data at EASL from the Phase 2a trial evaluating efinopegduvide, our investigational GLP-1/glucagon receptor co-agonist, in patients with NAFLD and initiated Phase 2b trial in pre-cirrhotic NASH
- FDA accepted re-submission of the NDA for gefapixant in patients with refractory or unexplained chronic cough

---

1. Centers for Disease Control and Prevention, IPD serotype data 2019, as compiled from data provided through Active Bacterial Coresurveillance (ABCs).
Accelerating our presence in immunology

- Deep expertise in clinical trial design and execution
- Global clinical trial scale
- Proven track record of developing and implementing precision medicine strategies
- Emerging immunology discovery pipeline

+ Focused expertise in immunology
- Deep genetic and biological insights from Prometheus 360 Data Science Platform
- Risk-stratified biomarker approach
- Suite of immunology pipeline compounds
Q&A

Rob Davis
Chairman & Chief Executive Officer

Caroline Litchfield
Chief Financial Officer

Dr. Dean Li
President, Merck Research Laboratories

Peter Dannenbaum
Vice President, Investor Relations
Appendix
# Q2 2023 GAAP financial results summary

$ in billions, except LPS/EPS amounts

<table>
<thead>
<tr>
<th></th>
<th>Q2 2023&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Q2 2022</th>
<th>Change</th>
<th>Change Ex-FX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>$15.0</td>
<td>$14.6</td>
<td>+3%</td>
<td>+7%</td>
</tr>
<tr>
<td>Operating Expenses</td>
<td>$16.0</td>
<td>$5.3</td>
<td>N/M</td>
<td>N/M</td>
</tr>
<tr>
<td>Tax Rate</td>
<td>-11.9%</td>
<td>12.0%</td>
<td>-23.9pts</td>
<td>N/A</td>
</tr>
<tr>
<td>GAAP Earnings / (Loss) per Share</td>
<td>($2.35)</td>
<td>$1.55</td>
<td>N/M</td>
<td>N/M</td>
</tr>
</tbody>
</table>

1. 2Q23 GAAP results include $10.2 billion or $4.02 of such charges related to the acquisition of Prometheus Biosciences.
Capital allocation: Trailing twelve months

Over the past 12 months

<table>
<thead>
<tr>
<th>Order of priority</th>
<th>Billions</th>
</tr>
</thead>
<tbody>
<tr>
<td>$10.4 (After-Tax R&amp;D)</td>
<td>$4.2 (CapEx)</td>
</tr>
</tbody>
</table>

Capital investments
2023 to 2027

~$15B

Over 5 years, including expanding manufacturing capacity for Oncology, Vaccines, and Animal Health. Includes >$10B in the U.S.

Well positioned balance sheet with capacity to fund additional value-enhancing business development opportunities

Commitment to the dividend

Dollars per share

+2% +2% +2% +2% +2% +15% +11% +7% +6% +6%


1. Includes payments reflected in operating cash flow
**Broad and innovative pipeline to solve significant unmet medical needs**

<table>
<thead>
<tr>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Under regulatory review</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncology</strong></td>
<td><strong>Oncology</strong></td>
<td><strong>Under regulatory review</strong></td>
</tr>
<tr>
<td><strong>MK-0482</strong></td>
<td><strong>KEYTRUDA (MK-3475)</strong></td>
<td><strong>KEYTRUDA (MK-3475)</strong></td>
</tr>
<tr>
<td>NSCLC</td>
<td>CSSC (EU)</td>
<td>2L HCC (US)</td>
</tr>
<tr>
<td><strong>MK-1308 (quavonilimab)</strong></td>
<td>Hepatocellular (EU)</td>
<td>LA Merkel Cell (US)</td>
</tr>
<tr>
<td>NSCLC</td>
<td>Mesothelioma</td>
<td>Adjuvant NSCLC (EU)</td>
</tr>
<tr>
<td><strong>MK-1308A</strong></td>
<td>Ovarian</td>
<td>HER2+ Gastric (EU)</td>
</tr>
<tr>
<td>(quavonilimab+ pembroli zumab)</td>
<td>SCLC</td>
<td>Resectable NSCLC (US, EU, JPN)</td>
</tr>
<tr>
<td>CRC</td>
<td></td>
<td>MK-1026 (nemtabrutinib)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>Hematological Malignancies</td>
<td>Hematological Malignancies</td>
</tr>
<tr>
<td>SCLC</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MK-2140</strong></td>
<td><strong>LENVIMA (MK-7902)</strong></td>
<td><strong>WELIREG (MK-7902)</strong></td>
</tr>
<tr>
<td>(cilverotarab vedotin)</td>
<td>Biliary</td>
<td>Esophageal</td>
</tr>
<tr>
<td>Bladder</td>
<td>Cancerous VHL tumors (EU)</td>
<td>Gastric</td>
</tr>
<tr>
<td>Breast</td>
<td>CRC</td>
<td>NSCLC</td>
</tr>
<tr>
<td>Gastric</td>
<td>Endometrial</td>
<td>NSCLC</td>
</tr>
<tr>
<td>Hematological Malignancies</td>
<td>Esophageal</td>
<td>SCLC</td>
</tr>
<tr>
<td>NSCLC</td>
<td>HCC</td>
<td></td>
</tr>
<tr>
<td>Ovarian</td>
<td>Pancreatic Rare Cancers</td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>TUKYSA (MK-7119)</td>
<td>Hematological Malignancies</td>
</tr>
</tbody>
</table>

**Vaccines**
- V181: Dengue Virus
- **MK-8591B** (islatravir+MK-8507)1: HIV-1 Infection
- **MK-8591D** (islatravir+lenacapavir)2: HIV-1 Infection

**Infectious diseases**
- **MK-0482**: Hypercholesterolemia
- **MK-2060**: Thrombosis
- **MK-5475**: Pulmonary Arterial Hypertension
- **MK-7962 (sotatercept)**: Pulmonary Hypertension due to Left Heart Disease

**Cardiovascular**
- **MK-636**: Treatment Resistant Depression
- **MK-6024**: (efinopegduvote)
- **NASH**

**Neuroscience**
- **MK-8894**: Schizophrenia

**Immunology**
- **MK-7240**: Ulcerative Colitis

**General medicine**
- **MK-1942**: Lipid Lowering Therapy
- **MK-6024**: (efinopegduvote)
- **NASH**

**Infectious diseases**
- **MK-8591A**: (doravirine+islatravir)2: HIV-1 Infection
- **LAGEVIRIO (MK-4482)3**: COVID-19 antiviral

**Vaccines**
- **MK-1942**: Dengue Vaccine, adult
- **MK-8591A**: Metastatic 1L Prostate (JPN)

**Cardiovascular**
- **MK-7962 (sotatercept)**: Pulmonary Arterial Hypertension

---

1 On FDA clinical hold  2 On FDA partial clinical hold for higher doses than those used in current clinical trials
3 Available in the US under EUA  4 Development is co-funded by Royalty Pharma
5 Requested re-examination of EU MAA following CHMP major objection of data to support market authorization
6 As of August 1, 2023